Our Science

Platform

Pipeline

Partnerships

Contact

  • Announcement

  • Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation

Better biologics for the toughest targets.

Keep scrolling

  • Announcement

  • Series A closed at $9.3M · Research agreement with the Cystic Fibrosis Foundation

DeDe novonovo antibodyantibody discoverydiscovery forfor GPCRsGPCRs andand challengingchallenging targets.targets. DesignedDesigned withwith GenerativeGenerative AI.AI.

DeDe novonovo antibodyantibody discoverydiscovery forfor GPCRsGPCRs andand challengingchallenging targets.targets. DesignedDesigned withwith GenerativeGenerative AI.AI.

The Data Advantage

AA decadedecade ofof pioneeringpioneering biologicsbiologics forfor thethe hardesthardest drugdrug discoverydiscovery targetstargets inin medicine.medicine.

AA decadedecade ofof pioneeringpioneering biologicsbiologics forfor thethe hardesthardest drugdrug discoverydiscovery targetstargets inin medicine.medicine.

AA decadedecade ofof pioneeringpioneering biologicsbiologics forfor thethe hardesthardest drugdrug discoverydiscovery targetstargets inin medicine.medicine.

Pioneers

Data Moat

Experience

Our models are built on specialized GPCR data, capturing structural features and complexities that broad protein models can overlook.

10 Years

Training data purpose built for GPCRs and transmembrane proteins, since 2017.

2000x

Greater hit rate vs naive library, in the discovery of functional agonist antibodies for a Class A GPCR.

>240

Proprietary stable cell lines for GPCRs and ion channels, which exponentially increase true binder discovery rates.

The advantage

LeadingLeading AI-poweredAI-powered discoverydiscovery 
ofof functional,functional, developabledevelopable biologicsbiologics forfor thethe mostmost challengingchallenging targets.targets.

LeadingLeading AI-poweredAI-powered discoverydiscovery 
ofof functional,functional, developabledevelopable biologicsbiologics forfor thethe mostmost challengingchallenging targets.targets.

LeadingLeading AI-poweredAI-powered discoverydiscovery 
ofof functional,functional, developabledevelopable biologicsbiologics forfor thethe mostmost challengingchallenging targets.targets.

  • Generative De Novo Design

    Novel chemical space, sequence or structure based.

  • Diverse antibody formats

    Any biologic format with a heavy chain (mAbs, VHH/VH-VL, etc.)

  • High success rates

    2000x greater hit rates vs naive libraries.

  • Accelerated lead generation

    Intergrated dry and wet lab enables an iterative feedback loop.

  • Faster generative cycles

    Prioritized clones maintain their natural conformation, enabling characterization in 1 month.

  • Generative De Novo Design

    Novel chemical space, sequence or structure based.

  • Diverse antibody formats

    Any biologic format with a heavy chain (mAbs, VHH/VH-VL, etc.)

  • High success rates

    2000x greater hit rates vs naive libraries.

  • Accelerated lead generation

    Intergrated dry and wet lab enables an iterative feedback loop.

  • Faster generative cycles

    Prioritized clones maintain their natural conformation, enabling characterization in 1 month.

More about the Antiverse Platform

SuccessfulSuccessful partnershipspartnerships withwith leadingleading pharmapharma companiescompanies andand organizations.organizations.

SuccessfulSuccessful partnershipspartnerships withwith leadingleading pharmapharma companiescompanies andand organizations.organizations.

Trusted by